The hazards of hazard ratios

Epidemiology

Volumn 21, Issue 1, 2010, Pages 13-15

  Hernán, Miguel A ^a  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

CLINICAL TRIAL; CONFIDENCE INTERVAL; COVARIANCE; DISEASE PREDISPOSITION; DRUG SAFETY; EXPOSURE; FOLLOW UP; HAZARD RATIO; HORMONAL THERAPY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MEASUREMENT ERROR; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SHORT SURVEY; SURVIVAL; SURVIVAL TIME; SURVIVOR; SYSTEMATIC ERROR;

EPIDEMIOLOGIC STUDIES; PROPORTIONAL HAZARDS MODELS;

EID: 73849111722     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181c1ea43     Document Type: Short Survey

References (10)

1. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
2. Prentice RL, Pettinger M, Anderson GL. Statistical issues arising in the Women's Health Initiative. Biometrics. 2005;61:899-911.
3. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625.
4. Flanders WD, Klein M. Properties of 2 counterfactual effect definitions of a point exposure. Epidemiology. 2007;18:453-460.
5. Hernán MA, Cole SR, Margolick JB, Cohen MH, Robins JM. Structural accelerated failure time models for survival analysis in studies with timevarying treatments. Pharmacoepidemiol Drug Saf. 2005;14:477-491.
6. Greenland S. Absence of confounding does not correspond to collapsibility of the rate ratio or rate difference. Epidemiology. 1996;7:498-501.
7. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75:45-49.
8. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease (with discussion). Epidemiology. 2008;19:766-779.
9. Toh SG, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal users of estrogen plus progestin hormone therapy: Does the increased risk ever disappear? Ann Intern Med. In Press.
10. Zhang Y, Thamer M, Cotter D, Kaufman J, Hernán MA. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2009;4:638-644.